Pioneering the Future of Cardiology – PMcardio Joins Forces with Cardiovascular Research Center Aalst in an AI-Driven R&D Partnership
PMcardio, a market leader in AI-powered cardiovascular diagnostics, is thrilled to announce a research and development partnership with the Cardiovascular Research Center Aalst.
PRESS RELEASE: PMcardio, a market leader in AI-powered cardiovascular diagnostics, is thrilled to announce a research and development partnership with the Cardiovascular Research Center Aalst, a world-renowned authority in cardiology. The transformative alliance blends PMcardio’s state-of-the-art technology with the globally acclaimed clinical expertise of the Heart Center Aalst, aspiring to unlock new dimensions in cardiac care and improve patient outcomes.
“Bridging the gap between medical technology and patient care, this collaboration emphasizes the game-changing role of AI in healthcare and its ability to revolutionize the diagnosis and management of cardiovascular diseases,” says Martin Herman, CEO of Powerful Medical, the deep-tech firm behind PMcardio.
The partnership represents a strategic step towards accelerating advancements in cardiac care. By harnessing the potential of AI technology, this alliance aims to facilitate rapid research improvements, enabling early disease detection and timely treatment, thereby redefining the current standards of heart care.
Dr. Jozef Bartunek, Co-director of the Cardiovascular Center Aalst, expresses his enthusiasm, “Our R&D partnership with PMcardio aligns perfectly with our continuous efforts to remain at the forefront of cardiovascular innovation and advancing standards of care. We are eager to combine our extensive clinical expertise in advancing PMcardio’s progressive AI technology developed on clinically validated data sets, which has shown exceptional potential in ECG diagnostics.”
The AI-powered clinical assistant, PMcardio, allows healthcare professionals to diagnose 38 cardiovascular diseases with cardiologist-level precision in under 5 seconds. This collaboration aspires to enhance this capacity, further empowering medical professionals to deliver swift, accurate, and personalised patient care.
“Our partnership with the Cardiovascular Research Center Aalst enables us to venture deeper into the pioneering territory of healthcare innovation and provides us with access to their extensive clinical research network,” explains Dr. Robert Herman, Chief Medical Officer at Powerful Medical. “Together, we aim to expand the AI-powered diagnostic ECG capabilities in early detection of Heart Failure, Acute Coronary Syndrome (ACS), and a host of predictive diagnostics, thereby ushering a new era of cardiac diagnostics and patient care.”
About Cardiovascular Research Center Aalst:
The Cardiovascular Research Center Aalst, a top-tier tertiary, non-university center in cardiology, provides innovative and comprehensive care for patients with cardiovascular disease. With a commitment to maintaining the highest standards of patient care, their work continues to make significant contributions to the field of cardiology worldwide.
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
